Pay in 4 interest-free payments of $6.82 Learn more
Ships within 48 hours · Estimated delivery Oct 12 - Oct 17
References Chang CH, Tsai WC, Lin MS, et al
compounded only NAD+ Infusion (IV) Not FDA-approved
Its broad interaction across regulatory pathways is one reason BPC-157 remains one of the most frequently cited peptides in experimental models
Research Background & Mechanistic Focus Current research use centers on coordinated cytoskeletal, cellular-migration, and structural-response signaling models, comparative presentation or formulation behavior where applicable, and controlled experimental models designed to evaluate compound-specific signaling activity within non-clinical laboratory systems
The MOQ is 500L
Both target multiple metabolic pathways simultaneously
US$ 28.67
US$ 29.38
US$ 29.20
US$ 28.09
